期刊
CANCERS
卷 11, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/cancers11101526
关键词
expression; FAK; lung cancer; small-cell lung cancer; non-small-cell lung cancer; multiplex immunofluorescence staining; phospho-FAK; prognosis; targeted therapy
类别
资金
- Televie (Fonds National de la Recherche Scientifique (FNRS)) [7.4624.15]
- Fonds Special de Recherche (FSR) (Communaute Francaise de Belgique)
- Fondation Willy and Marcy De Vooght
- Fonds de Recherche Clinique (FRC) from the Universite catholique de Louvain (UCLouvain), Belgium
- Fund for Research Training in Industry and Agriculture (FRIA) (FNRS), Belgium [1.E.108.19F]
- Fonds National de la Recherche Scientifique [1.R016.18]
- WELBIO, Belgium [CR-2012S-05]
- Fondation Mont-Godinne [FMG-2011-BR-02, FMG-2013-BR-02, FMG-2014-BR-01, FMG-2015-BR-02, FMG-2016-BR-02, FMG-2017-BR-04, FMG-2018-BR-01]
- Televie (FNRS) [7.4624.15, 7.4588.10F]
- FRIA (FNRS) [1.E.108.19F]
- FSR
- Secteurs des Sciences de la Sante, UCLouvain, Belgium
Introduction: Focal adhesion kinase (FAK) plays a crucial role in cancer development and progression. FAK is overexpressed and/or activated and associated with poor prognosis in various malignancies. However, in lung cancer, activated FAK expression and its prognostic value are unknown. Methods: FAK and activated FAK (phospho-FAK Y397) expressions were analyzed by multiplex immunofluorescence staining in formalin-fixed paraffin-embedded tissues from 95 non-small-cell lung cancer (NSCLC) and 105 small-cell lung cancer (SCLC) patients, and 37 healthy donors. The FAK staining score was defined as the percentage (%) of FAK-stained tumor area multiplied by (x) FAK mean intensity and phospho-FAK staining score as the (% of phospho-FAK-stained area of low intensity x 1) + (% of phospho-FAK-stained area of medium intensity x 2) + (% of the phospho-FAK-stained area of high intensity x 3). FAK and phospho-FAK staining scores were compared between normal, NSCLC, and SCLC tissues. They were also tested for correlations with patient characteristics and clinical outcomes. Results: The median follow-up time after the first treatment was 42.5 months and 6.4 months for NSCLC and SCLC patients, respectively. FAK and phospho-FAK staining scores were significantly higher in lung cancer than in normal lung and significantly higher in SCLC compared to NSCLC tissues (p < 0.01). Moreover, the ratio between phospho-FAK and FAK staining scores was significantly higher in SCLC than in NSCLC tissues (p < 0.01). However, FAK and activated FAK expression in lung cancer did not correlate with recurrence-free and overall survival in NSCLC and SCLC patients. Conclusions: Total FAK and activated FAK expressions are significantly higher in lung cancer than in normal lung, and significantly higher in SCLC compared to NSCLC, but are not prognostic biomarkers in this study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据